[vc_row css_animation=”” row_type=”row” use_row_as_full_screen_section=”no” type=”grid” angled_section=”no” text_align=”left” background_image_as_pattern=”without_pattern” z_index=””][vc_column width=”1/6″][/vc_column][vc_column width=”2/3″][vc_column_text]
GB Sciences One of Ten Companies Named in Important New Canadian Research Publication
[/vc_column_text][vc_empty_space height=”20px”][vc_column_text]Corporate strategy dedicated to scientific medical research, a viable drug development pipeline and a strong Intellectual Properties Patent Portfolio are cited as the key differentiating factors.
LAS VEGAS, July 9, 2018 /PRNewswire/ — GB Sciences, Inc. (OTCQB: GBLX) was named as one of the ten select cannabis companies in North America according to a study conducted by a leading investment banking firm in their June 20, 2018 Industry Report on Medical Cannabis. The report included deep research and analyst coverage on 31 public and 31 private cannabis companies from the US and Canada. GB Sciences was the only U.S. publicly traded company to make the list of ten companies.
The sixty-two target Companies were evaluated on the following criteria:
“Through our research, we have evaluated the clinical approach and fundamental technologies employed by a broad spectrum of companies participating in the clinical cannabis ecosystem. Here, we collect a group of 10 companies that we believe have the potential to capture the massive opportunities that lie in wait for those that focus on:
- The consistent, large-scale production of high-quality cannabinoids;
- The development of finely controlled, deeply studied cannabinoid drug formulations; and
- The generation of gold standard clinical data supporting the registration of proprietary cannabinoid formulations to address specific clinical indications.”
Analyst Coverage for GB Sciences Inc. (GBLX-OTC):
“GB Sciences is a Nevada-based medical and recreational cannabis producer that is already generating revenue from its Las Vegas operations. What excites us most about GB, however, is its clinical discovery program. Chief Science Officer, Dr. Andrea Small-Howard, is using in silico data analysis to identify indications with well-established in vitro and in vivo model systems. By then applying molecular profiling of distinct cannabis strains, she is to undertake pharmaceutical-quality high-throughput screens of varying combinations of individual cannabinoids to identify profiles of up to 12 compounds in very specific ratios that can be applied to ameliorate specific disease indications. This rigorous, very pharmaceutical approach which does not hide behind the concept of the “entourage effect”, makes GB quite unique among U.S., and even Canadian cannabis producers.”
The ten select cannabis companies list:
- (WEED-T | CGC)
- Cansortium Holdings LLC (Private)
- Avicanna Inc. (Private)
- Tetra Bio-Pharma Inc. (TBP-T)
- GB Sciences Inc. (GBLX-OTC)
- Cardiol Therapeutics Inc. (Private)
- Tilray (Private)
- InMed Pharmaceutical Inc. (IN-T)
- Technology: Ample Organics Inc. (Private) & Strainprint Technologies Ltd. (Private)
- Village Farms International Inc. (VFF-T) / Emerald Health Therapeutics, Inc. (EMH-T)
GB Sciences has filed seven patents that cover over 100 separate and specific disease states. This fact, coupled with high profile research University partnerships on a global scale, singled the Company out as the only viable publicly traded U.S. candidate that fit the Top Ten evaluation criteria:
“As clearer signals of clinical cannabis’ efficacy in specific indications emerges from robust clinical evidence, the medical community—whose anathema is anecdote—will have the data-driven support it requires to adopt these drugs. With greater support from physicians comes greater buy-in from Pharma: soon, we may see clinical cannabis companies access markets much broader than those occupied by medical and adult use cannabis today, which, we suspect will be catalytic in spurring robust Pharma-cannabis transactions. For medical cannabis alone, we suspect that the well is much, much deeper than what today’s companies are drawing from at present.”
In addition to their robust IP portfolio, GB has solved a conundrum the Company terms as the Big Green Riddle (https://www.gbsciences.com/company-overview/), which is the consistent, large-scale production of high-quality cannabinoids for medical formulations.
As Company Chairman and CEO John Poss explained, “The original vision for this company was to create an innovative drug development pipeline that put efficacious drugs in the hands of patients. All company endeavors revolve around this basic tenet. Even our adult use division is dedicated to producing the same trusted quality, purity and consistency in each and every one of our recreational products,” he continued, “To GB Sciences, all cannabis consumers are patients of one sort or another. And they all deserve the same trusted raw ingredients and high product standards. Our products are based on sound scientific principles and grounded in human service… and we’re proud of that.”
[/vc_column_text][vc_empty_space height=”20px”][vc_single_image image=”2972″ img_size=”full” alignment=”center” qode_css_animation=””][vc_empty_space height=”20px”][vc_column_text]About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company’s goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: https://www.gbsciences.com.
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company’s research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
Tom Arcuragi, EVP, email@example.com
www.gbsciences.com[/vc_column_text][vc_empty_space height=”20px”][/vc_column][vc_column width=”1/6″][/vc_column][/vc_row]